FDA Adds Warning to SGLT2 Inhibitors

    loading  Checking for direct PDF access through Ovid

Abstract

The FDA will require manufacturers of the SGLT2 inhibitor class to conduct a five-year pharmacovigilance study.

Related Topics

    loading  Loading Related Articles